spacer
home > white papers > How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction - Temptime Corporation
WHITE PAPERS
logo_Temptime_C.png

Temptime Corporation

phone +1 973 984 6009
email info@temptimecorp.com
web http://temptimecorp.com/edge-wireless-connected-sensors/
email 116 The American Road, Morris Plains, 07950, New Jersey

How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction

The specialty pharmacy industry could reduce costs by $27.5 million annually (product and call center staff costs only) if visual temperature indicators were used as decision-making tools to determine if medicine should be used or returned when patients suspect heat damage. In addition, 97% of patients surveyed, who received medicine from specialty pharmacies with a visual temperature indicator included in the package, agree that they would want an indicator in all shipments and 95% agree the indicator increased their confidence in the medicines received.
How to Reduce Costs of Specialty Pharmaceutical Shipments and Increase Patient Satisfaction
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Scitara and Veeva Partner to Help Companies Optimize QC Lab Productivity


More info >>


White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was 271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement